BIOR Biora Therapeutics, Inc. EV/EBITDA Multiple

Brandmark of Biora Therapeutics, Inc. (BIOR)

Intellectual property protection for intelligent capsules creates barriers for competitors, yet requires colossal investments for regulatory approval. A lack of sales and early-stage platform testing leave Biora Therapeutics (BIOR) dependent on external financing. Future revenues rely on the implementation of Bio-Jet systems for targeted gastrointestinal therapy. This chart illustrates an EV/EBITDA level of .

BIOR (Biora Therapeutics Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 07/04/2022 to 11/13/2026

Analytical breakdowns for Biora Therapeutics

- current price and projected stock value:
Stock Price Progenity|BIOR - Analyst Target Range
- market capitalization data:
Market Capitalization Biora Therapeutics, Inc|BIOR - Company Buyout Price
- issuer book value statistics:
Accounting Value per Share Biora Therapeutics|BIOR - Total Net Assets|Market Capitalization to Book Value Ratio bioratherapeutics.com|BIOR - Aggregate Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Biora Therapeutics|BIOR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Biora Therapeutics, Inc.|BIOR - Company Cumulative Debt|Debt to Book Capitalization Ratio Biora Therapeutics, Inc|BIOR - Company Long-Term Loans and Borrowings|Company Short-Term Debts Biora Therapeutics|Quick Liquidity Indicator bioratherapeutics.com
- net income and valuation multiples indicators:
BIOR - Final Profit|Future Profit Biora Therapeutics|BIOR - Market Price to Net Income Ratio|Forward P/E Multiple Biora Therapeutics|BIOR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Biora Therapeutics, Inc|BIOR - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Biora Therapeutics|BIOR - Earnings per share for the trailing year|Quarterly EPS earnings growth bioratherapeutics.com|BIOR - Earnings growth in current year|Net earnings per share growth forecast for next year Biora Therapeutics
Initial company analysis:BIOR (Progenity)
Product sample of Biora Therapeutics, Inc.

Professional selection of resilient assets begins with an analysis of the ratio of total business value to its operating profit. This Enterprise Value to EBITDA level allows for the assessment of market capitalization inclusive of net debt, excluding the impact of tax regimes and depreciation. For Biora Therapeutics (BIOR), this indicator confirms investment attractiveness, bolstered by the scientific community's high level of confidence in their innovative biologic delivery system.

Key competitors

EV/EBITDA Multiple PHAT (Phathom Corp)|Enterprise Value to EBITDA Multiple Terns Corp|Ironwood Pharmaceuticals Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Curanex Pharmaceuticals Inc CURX|IMRN (immuron.com.au) - Enterprise Value to EBITDA Ratio|EVOK: Enterprise Value to Operating Income Before Depreciation Ratio|ENTO (Entero Therapeutics Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization RDHL|EV/EBITDA Multiple PALI|Total Company Value to Operating Income Before Depreciation Ratio jaguar.health|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Morphic MORF